For Pediatric and Young Adult Patients with Sarcoma, Cixtumumab Plus Temsirolimus May Not Be Effective
the Cancer Therapy Advisor take:
According to a new study published in the journal Pediatric Blood and Cancer, cixtumumab plus temsirolimus did not cause objective responses in pediatric and young adult patients with recurrent or refractory sarcoma.
For the phase 2 study, researchers sought to investigate the use of cixtumumab, an insulin-growth factor type 1 receptor inhibitor, and temsirolimus, a mammalian target of rapamycin inhibitor, for the treatment of pediatric and young adult patients with recurrent or refractory Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, and other types of soft tissue sarcoma.
The combination had previously demonstrated positive preclinical data, and doses from a pediatric phase 1 study were used for this study. Patients received cixtumumab 6mg/kg IV and temsirolimus 8mg/m2 IV once weekly for 4 weeks, followed by cixtumumab 6mg/kg and temsirolimus 10mg/m2 for subsequent cycles. Of those enrolled, 43 patients were evaluable and received a median of 2 cycles.
Results showed that no patients experienced objective responses. Of those, 16% were progression-free at 12 weeks. The most common adverse effects were electrolyte disturbances, mucositis, and myelosuppression.
Most patients were not dose-escalated with temsirolimus due to toxicities. Because no objective responses were observed, researchers could not investigate the correlation between tissue biomarkers and objective response.
Cixtumumab plus temsirolimus did not cause objective responses in pediatric and young adult patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Plastics and Cancer
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer